HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avon third quarter

This article was originally published in The Rose Sheet

Executive Summary

International business drove sales up 11.2% in the third quarter to $1.78 bil., the direct seller announces Oct. 29. Beauty sales for the period increased 15% to $1.23 bil. Sales in Latin America grew 8% in dollars, while in Europe, sales jumped 24% and in Asia Pacific, 14%. Gains offset U.S. sales decline of 1% to $502.6 mil., "reflecting weak consumer response to color cosmetics promotions in advance of a later September category relaunch, and under-performance in children's apparel and toys," Avon says. Operating profit in the region fell 9%. Going forward, the firm intends to exit certain categories of Beyond Beauty, which declined 6% in Q3, to restore the U.S. business to healthy growth. Avon consolidated net income jumped 32.9% to $176.9 mil. in the quarter ...

You may also be interested in...



Avon Strategy To Revive U.S. Sales Includes Anew Clinical Extensions

Avon will expand its Anew Clinical skin care range in the second quarter with the launch of Laser and Lift & Tuck, positioned as an at-home alternative to liposuction, the firm said

JT Gains World-First Topical JAK Inhibitor Approval

Latest new drug approvals in Japan include the first anywhere for a topical JAK inhibitor and also a marketing clearance for a new contender in the large prostate cancer space.

QUOTED. 27 January 2020. John McKay.

Consultant John McKay encourages device makers to ask questions of the US FDA’s inspection team during a facility audit. Check out his advice here.

UsernamePublicRestriction

Register

RS012561

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel